ストックスクリーナーアプリを入手
3.78
7.74%
-0.29
Atea Pharmaceuticals Inc (AVIR) 最新ニュース
Aug EndMonth: Can The AZEK Company Inc stock double in the next yearJuly 2025 WrapUp & Real-Time Market Trend Scan - baoquankhu1.vn
Institutional Investors Are Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Biggest Bettors and Were Rewarded After Last Week's US$56m Market Cap Gain - 富途牛牛
Can Atea Pharmaceuticals Inc expand into new marketsEarnings Recap Report & Risk Managed Trade Strategies - baoquankhu1.vn
Spotlight On Atea Pharmaceuticals And 2 Other Noteworthy Penny Stocks - Yahoo Finance
Is Atea Pharmaceuticals Inc. still a buy after recent gainsBlue Chip Stock Analysis & Daily Tips From Top Market Analysts - bollywoodhelpline.com
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens - Pharmaceutical Technology
Dip Buying: Can Atea Pharmaceuticals Inc stock double in the next year2025 Bull vs Bear & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Buyout Rumor: Is Atea Pharmaceuticals Inc a momentum stockTrend Reversal & Expert Curated Trade Setups - baoquankhu1.vn
Wall Street Recap: Will Atea Pharmaceuticals Inc face regulatory challengesTrade Volume Report & Long-Term Investment Growth Plans - baoquankhu1.vn
Atea Pharmaceuticals Highlights Phase 3 HCV Timeline, Unveils New Hepatitis E Candidate AT-587 at JPMorgan Conference - MarketBeat
Options Flow: Will Atea Pharmaceuticals Inc stock maintain dividend yieldJuly 2025 Patterns & Smart Money Movement Tracker - Bộ Nội Vụ
Bullish Atea Pharmaceuticals Insiders Loaded Up On US$5.40m Of Stock - Yahoo Finance
How Atea Pharmaceuticals Inc. stock performs in weak economyJuly 2025 Technicals & Entry Point Confirmation Alerts - Улправда
What is the fair value of Atea Pharmaceuticals Inc. stock nowEarnings Miss & Community Consensus Stock Picks - ulpravda.ru
Risk Off: Will Atea Pharmaceuticals Inc stock attract more institutional investorsTrade Exit Report & Risk Adjusted Buy/Sell Alerts - Bộ Nội Vụ
Atea Pharmaceuticals to highlight strategic priorities for FY26 - Yahoo Finance
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Will Atea Pharmaceuticals Inc. stock attract more institutional investorsTrade Ideas & Safe Capital Growth Stock Tips - ulpravda.ru
Why Atea Pharmaceuticals Inc. stock is popular among millennials2025 Trading Volume Trends & Community Consensus Trade Alerts - Улправда
Will Atea Pharmaceuticals Inc. stock deliver strong dividend growthGlobal Markets & Precise Buy Zone Identification - ulpravda.ru
Atea Pharmaceuticals Highlights 2026 Strategic Priorities - TradingView — Track All Markets
Atea Pharmaceuticals Advances Phase 3 Trials for HCV Treatment Regimen, Anticipates Significant Milestones in 2026 - Quiver Quantitative
New hepatitis C and E treatments move toward key human clinical trials in 2026 - Stock Titan
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Is Atea Pharmaceuticals Inc. stock supported by strong cash flows2026 world cup usa national team qualification star players pressing system winner prediction breakdown - ulpravda.ru
Critical Survey: Atea Pharmaceuticals (NASDAQ:AVIR) vs. Regeneron Pharmaceuticals (NASDAQ:REGN) - Defense World
What analysts say about Atea Pharmaceuticals Inc stockTrading Volume Trends & Build a Smarter Portfolio Right Now - earlytimes.in
What drives Atea Pharmaceuticals Inc stock priceWeekly Market Snapshot & Access Free Risk Analysis Before You Invest - earlytimes.in
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 1.4% – Here’s What Happened - Defense World
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 1.4%Here's What Happened - MarketBeat
Rapt Therapeutics (NASDAQ:RAPT) & Atea Pharmaceuticals (NASDAQ:AVIR) Head-To-Head Contrast - Defense World
Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026 - Seeking Alpha
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus - Sahm
Is Atea Pharma Moving BEYOND The Virus And FORWARD To Breakthroughs? - RTTNews
Atea Pharmaceuticals Completes Enrollment in North American Phase 3 Trial of Hepatitis C Treatment - marketscreener.com
Atea Pharmaceuticals Completes Enrollment in C-BEYOND Phase 3 Trial for HCV Treatment, Anticipates Topline Results in Mid-2026 - Quiver Quantitative
Atea Pharmaceuticals Completes Patient Enrollment In North American Phase 3 Trial Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus - TradingView — Track All Markets
Atea Pharmaceuticals Completes Patient Enrollment in North - GlobeNewswire
Published on: 2025-12-21 17:47:39 - Улправда
Why analysts upgrade Atea Pharmaceuticals Inc. stockEarnings Overview Report & Stepwise Swing Trade Plans - Улправда
Is Atea Pharmaceuticals Inc. stock attractive for ETFsJuly 2025 Macro Moves & Safe Entry Trade Reports - Улправда
What technical charts say about Atea Pharmaceuticals Inc. stockJuly 2025 Breakouts & Safe Capital Growth Plans - Улправда
How rising interest rates impact Atea Pharmaceuticals Inc. stockEntry Point & Long Hold Capital Preservation Plans - DonanımHaber
Will Atea Pharmaceuticals Inc. stock maintain growth storyTrade Performance Summary & Free Real-Time Volume Trigger Notifications - DonanımHaber
Chart Watch: Is Atea Pharmaceuticals Inc. stock supported by strong cash flowsJuly 2025 PreEarnings & Weekly Stock Breakout Alerts - Улправда
Nano Dimension And 2 Other Penny Stocks With Promising Potential - simplywall.st
Atea Pharmaceuticals Earnings Notes - Trefis
Atea Pharmaceuticals (AVIR) Stock Analysis Report | Financials & Insights - Benzinga
Atea Pharmaceuticals (NASDAQ:AVIR) Trading Down 1.9%Should You Sell? - MarketBeat
We're Keeping An Eye On Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Rate - Yahoo Finance
1.31%
3.45%
大文字化:
|
ボリューム (24 時間):